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Background: The objectives of this study were to describe and compare chlamydia testing provided by general
practitioners (GPs) in four selected European countries with well-developed primary health care systems and high
reported chlamydia rates; we aimed to compare contrasting countries where chlamydia testing is provided by GPs
(England, Sweden) with countries where primary care chlamydia testing is absent or very limited (France, Estonia).
Methods: For data generation a structured questionnaire was developed and secondary data sources were
searched. The questionnaire developed by the research team allowed a systematic approach to analysing
chlamydia care (including testing in general practice) and the gathering of relevant data.
Results: There were no significant differences in the burden of the disease or the type of general practice care
provision in the study countries. In all four countries, testing for chlamydia (with nucleic acid amplification test,
NAAT) is available in the public sector, a substantial proportion (>60%) of young people aged 16–25 years visit their
general practitioner (GP) annually, and reimbursement for chlamydia testing costs to the relevant parties (GPs in
England, Sweden and Estonia; and patients in France) by the national health insurance system or its equivalent.
In countries where chlamydia testing is provided by GPs (England, Sweden) a national strategy or plan on STI
control that specifically mentions chlamydia was in force, chlamydia care guidelines for GPs were in place and STI
management was more firmly established in the GP residency training curriculum, either formally (England) or
informally (Sweden), than in the other countries.
Conclusion: Future research on the effectiveness of chlamydia screening (also in the context of general practice
care) and program provision should reflect national needs and the prevention of complications.
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As the most frequently reported notifiable communicable
disease in Europe and North America, chlamydia is the
focus of concerted public health control efforts based on
screening and treatment [1,2]. A systematic survey of chla-
mydia control activities conducted recently in 28 Euro-
pean Economic Area (EEA) countries [3] found wide
variation in the organisation of chlamydia control: 60%
(17/28) of countries reported no organised activity, while
39% (11/28) of countries had a strategy or plan for sexually* Correspondence: anneli.uuskula@ut.ee
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unless otherwise stated.transmitted infections (STI) control in place (in 6 of those
11 chlamydia control was specifically mentioned in the
strategy or plan). In 2012, clinical guidelines for chlamydia
case management were available in 79% of these countries
(22/28); including guidelines specifically for general practice
or primary care physicians (GP) in 46% of the countries
(13/28) [3]. Opportunistic testing of asymptomatic individ-
uals was recommended in guidelines of 39% of countries
(11/28) but the UK is the only country with an organised
chlamydia screening programme after the Netherlands
stopped its pilot programme in 2012 [3].
Effective diagnosis and treatment of people with symp-
toms suggestive of chlamydia, followed by tracing andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ical practice at the individual level [4]. However as the
majority of infected people are asymptomatic and part-
ner notification is often incomplete infected individuals
can continue to transmit chlamydia to re-infect an exist-
ing partner, or to infect a new sexual partner. Therefore,
if used alone symptomatic case management is unlikely
to have an impact on chlamydia prevalence or long-term
complications at the population level. Approaches for
chlamydia control at the public health level include pri-
mary prevention activities, increased access to testing
and treatment for people with or at risk of infection, and
screening either opportunistically or as part of an orga-
nized population screening program. The effectiveness
and the best approach to screening (where and whom to
screen, how often, and what level of screening uptake is
required to reduce prevalence in practice) is not yet clear.
A diversity of services might be required to provide
comprehensive access to patients with, or at risk of, in-
fection. General practitioners are potentially significant
providers for chlamydia testing and screening [5-7]. Es-
pecially acknowledging the recent technological develop-
ments (e.g. nucleic acid amplification test (NAAT) based
testing of non-invasive genital specimens) and wider ac-
cess to adolescent/young adult population groups than
for many other medical specialists [8-10].
The objectives of this study were to describe and com-
pare chlamydia testing provision in four selected European
countries with well-developed primary health care systems
and high (reported) chlamydia rates; we aimed to compare
contrasting countries where chlamydia testing is pro-
vided by GPs (England, Sweden) with countries where
primary care chlamydia testing is absent or very limited
(France, Estonia).
Organisation of primary care/general medicine in
participating countries
England
Health care in the United Kingdom (UK) has been cen-
trally funded through the National Health Service (NHS).
The NHS provides both primary and specialist health care
which is largely free at the point of delivery. Recent re-
forms include a wide range of national quality improve-
ment initiatives and a pay for performance scheme that
accounts for around 25% of family practitioners’ income.
General practitioners are responsible for registered popu-
lations of patients. The practices staffing varies in size
from single general practices (GPs) to large practices with
20 or more staff (typically working in groups of 4–6 self-
employed physicians). They hire nurses and a range of
other ancillary staff, and act as gatekeepers to most spe-
cialist care [11]. Patients may also directly access specialist
genito-urinary medicine, out of hours primary care and
emergency services which are usually based in the hospitalsetting. Practice list sizes therefore vary between ~500 to
20,000 or more.
The core general practitioner (GP) contract is managed
by NHS England, and additional public health services in-
cluding sexual health are commissioned by local author-
ities. Some local authorities offer additional payments for
an enhanced level of service provision. Patients can choose
to register with any practice that covers the area they are
resident in and everyone can access NHS GP services
without charge. Certain services which are not considered
necessary or cost effective such as travel vaccinations, cos-
metic and minor surgery are not provided on the NHS.
Estonia
The Health Services Organization Law of 2002 estab-
lished the regulatory framework for primary care and
family medicine whereby primary care is organized as
the first level of contact with the health system and is
provided by independent general practitioners (in
Estonia: family physicians) –– who are contracted by the
Estonian Health Insurance Fund and paid according to
the number of patients registered on the list (according
to a weighted per capita payment system) and fee-for-
service. Since 2006, basic allowances have been comple-
mented by a quality bonus system, which aims to foster
disease prevention and management of selected chronic
conditions. The regulations specify that a practice list
size should be around 1600 ± 400 persons. Patients are
free to choose the general practitioner with which they
register, and can change their GP when they wish. All
GPs are required to work with at least one practice
nurse (in order to receive payment from the Estonian
Health Insurance Fund). The income from the Estonian
Health Insurance Fund is used by the family physician to
meet the practice running costs, purchase of equipment,
cost of essential diagnostics, and for remuneration of
employed staff (such as nurses or administrative staff ).
In Estonia, GPs work as partial gatekeepers: referral
from a GP is needed for almost all specialist care, except
for (dermato)venerology, psychiatry, ophthalmology, gy-
naecology and traumatology in the case of acute trauma.
France
There is no general law defining primary care in France.
Most health care providers in primary care working in
private practice are regulated by a contract between the
GP and the national health insurance.
Most primary care providers work on a fee for service
basis. In order to be optimaly refunded, each citizen has
to register with a doctor designated as their attending
physician”, the patient has to attend this doctor in order
to be reimbursed in case of referral to some other spe-
cialists (but not for consultation with gynaecologists,
paediatricians, ophthalmologists or psychiatrists). Most
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of these are with a GP (98%). There is no capitation fee
related to the contract, and no commitment of any kind
either for the doctor, or the patient, and no duration for
the contract (patients can change “médecin traitant” at
any time). GP practices are mainly single-handed. The
number of group practices is increasing but very few of
them include other healthcare providers (nurses, special-
ists, psychotherapists) [12].
Sweden
Primary care, delivered by public (owned by the county
councils) and private (mostly owned by companies or co-
operation) primary care units in Sweden, involves services
that do not require advanced medical equipment and is
responsible for guiding the patient to the right level within
the health system. Team-based primary care facilities with
four to six GPs, and other staff categories (district nurses,
nurses and often physiotherapists, occupational therapists,
psychologists, and social welfare counsellors), is the most
common form of primary care practice in Sweden. Ideally,
each GP will have 1,500 patients registered, in fact most
have 2,000 or more registered patients in care.
Payment to primary care providers is generally based
on capitation for registered patients, weighted with
their estimated ‘illness burden’, fee-for-service and
performance-based payments [13]. Primary care in
Sweden for most surgeries falls within the budget of the
County Council. Either the GPs and staff are employed
by the County Council or they are private with a con-
tract with the County Council.
Methods
The methods for collection and analysis of the data was
agreed between the research team members and are pre-
sented below. The design was a cross-sectional review to
collect national level data from participating countries.
Research team
The participating researchers from 4 countries brought to
the team different perspectives and expertise. The study
team consisted of a university researcher in public health/
dermatovenerologist (STI physician) (AU; Estonia), a gen-
eral practitioner (RK; Estonia); a County Medical Officer
(HF; Sweden) and a Registered Nurse for Communicable
Diseases (JH; Sweden); two public health physicians (BD
and PD; France), and a consultant microbiologist (CMcN;
England) and a primary care researcher (EJR; England).
For data generation a structured questionnaire was de-
veloped and secondary data sources searched. A struc-
tured questionnaire developed by the research team
allowed a systematic approach to analysing the chlamydia
care (including testing in general practice) and the gather-
ing of relevant data.The rationale for this analysis and methodology were
evaluated by 8 study team members and discussed dur-
ing research meetings throughout the analysis develop-
ment process.
Questionnaire development
A structured questionnaire was developed by the study
team and discussed at a face to face meeting in English
(Additional file 1). The questionnaire asked about: the oc-
currence of chlamydia cases reported in participating
countries; national data on the existence and content of
guidelines on the management of chlamydia; details of
programmes for surveillance and how data was collected;
chlamydia care provision across the health service; and
primary health care provision. In addition, specifically for
general practice settings, the following information was
obtained: volume of practice participation in chlamydia
screening; how GP staff usually managed chlamydia and
laboratory diagnosis, payment of GP staff for chlamydia
and STI care.
The research team representatives in each country were
asked to fill in the questionnaire and to ask other local ex-
perts (general practitioners, commissioners of sexual
health services, public health practitioners, medical educa-
tion specialists, health administrators) for help if they were
uncertain of the answers themselves. Representatives were
also asked to send background information, such as strat-
egy documents and guidelines. Following the face to face
meeting the questionnaire was finalised and emailed in
February 2013 to the study researchers in each country. A
member of the research team (AU) monitored answers,
responded to questions and sent reminders. A bias in the
analysis was mitigated in each country by another health
professional with a national interest in sexual health (for
example in England the National Chlamydia Screening
Programme) or GP care provisjon (for example from
Department of Family Medicine of the University of Tartu)
checking the responses, and by detailed review of the data
at a face to face meeting and several teleconferences and
by email by the research team.
Country representatives reviewed the preliminary
analysis; the data used in this report include all re-
sponses, amendments and clarifications received by
September 2013.
Background data from secondary sources were col-
lated, and included a review of published literature relat-
ing to chlamydia management in the selected countries.
This analysis was supplemented by documentary analysis
of published reports, key legal instruments and policy doc-
uments (European CDC reports on STI surveillance and
chlamydia control [14,15]; country specific surveillance
and administrative data as necessary). To assess the publi-
cation productivity (number of publications) of countries
on chlamydia research and specifically on chlamydia
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a systematic literature search was conducted in PubMed
using the following search terms: all - (“chlamydia”[-
MeSH Terms] OR “chlamydia”[All Fields]) AND
(“1991”[CRDAT]: “3000”[CRDAT]) AND “humans”
[MeSH Terms] AND [country]; GP setting - (“chlamydia”
[MeSH Terms] OR “chlamydia”[All Fields]) AND
(“1991”[CRDAT]: “3000”[CRDAT]) AND “humans”[MeSH
Terms] AND “general practice”[MeSH Terms] OR (“gener-
al”[All Fields] AND “practice”[All Fields]) OR “general
practice”[All Fields] AND [country].
The study team conducted systematic debriefings and
cross-comparisons of the data compiled and its inter-
pretation. Discrepancies between the researchers in in-
terpretation were followed by in-depth discussion about
the observations that led to those conclusions and add-
itional data collection or consultations until the discrep-
ancy was resolved.
The analysis presented here is based on the use of data
or records that contain only non-identifiable data about
people, e.g. publicly accessible records, archives or publi-
cations. The ethics committee of the University of Tartu
has waived the requirement for ethics approval as this
does not constitute research on human subjects. The
study procedures were in accordance with local data
protection regulations in all participating countries.
Results
Occurrence of chlamydia in study countries
Data on the incidence (number of reported cases in the
population) and prevalence of genital chlamydia infec-
tion based on population-based studies is presented in
Table 1. Sweden has the highest rate of chlamydia infec-
tions per 100,000 reported by surveillance. Availability ofTable 1 Occurrence of genital chlamydial infection and resea
England Estonia
Number of reported cases,
all age groups, 2010
215 501 (206 912 in 2012) 1 686 (1 5
Rate per 100 000 population, all age
groups, in 2010 (and 2012)
348/100 000
(1979/100 000 in 2012*)
126/100 0
in 2012)
Trend (chlamydia rate per
100 000 in 2006) [14]
Increasing (190/100 000) Decreasin
Chlamydia trachomatis prevalence
(population-based studies)
6.2% in women and
5.3% in men [17] 4.5%




Research on chlamydia: number of
publications referenced in PubMed,
1991-current (all publications on
chlamydia/publications
on chlamydia where GP settings are
specified or mentioned (% of all))
1092/ 85 (7.8%) 16/ 1 (6.3%
*Data for 2012: England - Chlamydia Testing Activity Dataset 2012 (http://www.chlamy
ee/nakkushaigused/nakkushaigustesse-haigestumine.html); Sweden - Swedish Institute
**Extrapolated from the Goulet V et al. 2011 [32].surveillance data from France is limited. According to
the rate of new cases among 18–24 year olds in France
(240-360/100,000), the estimated rate for all ages in
France is likely to be similar to that reported from
Estonia, rather than that in the England or Sweden.
Chlamydia prevalences (derived from population based
studies) range from 3.2% (France) to 6.2% (England) for
women and 2.5% (France) to 5.3% (England) for men
[16-19]. In the population-based studies, the gender dif-
ferences of chlamydia prevalence in these countries were
insignificant.
Only a small fraction of the research on chlamydia
has focused on care issues in general practice settings
(<8% of the total research production on chlamydia in
England; ~1% in France and Sweden).
Chlamydia care and management in participating
countries
There are written guidelines for health professionals (not
necessarily primary care) covering diagnosis and case
management of chlamydia in three of the four countries
(England [7,20], Sweden [21], Estonia [22]. In France,
there are recommendations published by the national
health authority for chlamydia laboratory diagnostics
and screening [23,24]. In these guidance documents
chlamydia screening (i.e. testing of asymptomatic indi-
viduals) is recommended in all four countries for se-
lected target groups: youth (England, France), pregnant
women (Sweden, Estonia) and those exhibiting high risk
sexual behaviour (England, Sweden, France). Retesting
after positive chlamydia test (chlamydia treatment) is
recommended at 3 months for all positive tests to check
for repeat infection (in England), or for test of cure (in
Sweden, Estonia). Partner notification and testing is alsorch on chlamydia in study countries
France Sweden
96 in 2012) Data not available 36 800 (37 700 n 2012)
0 (119/100 000 360 for women 240 for
men (aged 18–24, in 2006)**
391/100 000
(395/100 000 in 2012)
g (188/100 000) NA Increasing (360/100 000)
omen and
en [19]
3.2% in women and
2.5% in men [16]
No data
) 343/ 4 (1.2%) 460/5 (1.1%)
diascreening.nhs.uk/ps/data.asp); Estonia – Health board (http://www.terviseamet.
for Infectious Control.
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care providers (Estonia, France), or in guidelines for
sexually transmitted infections/genitourinary medicine
(STI/GUM) clinics (England). Sweden has specific partner
notification guidelines [25]. Laboratory-based (England)
and provider-based (Estonia, Sweden) infectious diseases
surveillance systems for chlamydia are in place in three
countries (England, Sweden, Estonia). A national screen-
ing program is in operation in England (Table 2) and has
been pilot tested in France as part of a recent campaign by
the Health Education Institute (the results from the cam-
paign have not yet been made public).
Delivery of chlamydia care is spread between several
health care settings: STI/GUM clinics (England; main
site for men in Sweden, and in Estonia), gynaecology ser-
vices (main site for women in Estonia), general practi-
tioners (Sweden, England) and youth/family planning
clinics (France, youth in Estonia, Sweden) (Table 2).
Internet-based self-sampling is also available in England
(a free service, FreeTest Me, is available), Sweden (a free
service in the majority of counties), and Estonia (not free
of charge).
Primary care provision and chlamydia care in
participating countries
There are some clear similarities in the structure of GP
care provision in England, Estonia and Sweden. Small
group (2–3 GP) practices are the typical setting for pri-
mary care provision, although in England, a sizeable pro-
portion of practices are larger (38% - medium 5–9 GPs). In
contrast, the typical GP service in France would be a
single-handed practice. In England, Sweden and Estonia,
nurses work in GP practices, but not in France (Table 3).
Over two thirds of the youth at target age (16-24 years old)
visit their general practitioner at least once a year [26-28].
The official policy of GP training in STI care (includ-
ing chlamydia) varies in the 4 countries – from no train-
ing during GP residency (France), training some GPs but
not all (England), to some training offered to all GPs
(Sweden, Estonia), whether formally required (Estonia)
or not (Sweden) (Table 3).
Provision of chlamydia care (testing, treatment, coun-
selling) in GP services is regularly done in England and
Sweden however in Estonia and France only a small pro-
portion of GP practices provide chlamydia care (Table 4).
For men self-taken specimens (urine) and for women
physician-collected (cervical) swabs are the sampling
methods of choice (with an exception of Sweden where
for women self-collected vaginal swabs are used, and
England where women are either asked to use a self-
collected vaginal swab or urine test). For genital chla-
mydia infection testing, urine is generally collected from
men for both symptomatic disease and screening. For
women, physician-collected cervical swabs are advisedfor symptomatic cases and self-collected vaginal swabs
for screening purposes (Table 4).
Payment for chlamydia care in GP settings
Payment of health care services for the diagnosis and
treatment of individuals with chlamydia for GPs varies in
the study countries (Table 5). National insurance (Estonia)
or a National health managing system (England, Sweden)
reimburses the costs to GPs. In these countries, GPs are
expected to provide most health care (including chlamydia
care) within a particular budget per patient. Importantly
there are local drivers that potentially modify chlamydia
testing in general practices. In England, a diagnosis rate for
chlamydia is included in the Public Health Outcomes
Framework [29], used by sexual health commissioners to
plan work aimed at achieving recommended testing rates
(2,300 per 100,000 population) [30]. In response to that,
some Local Commissioners in England choose to incentivise
GPs to screen more patients by paying them to reach diag-
nostic targets, and/or encourage GPs to screen by stressing
the importance of screening as a public health measure.
In Estonia, health care service costs are covered by
National health insurance. The limited budget leads to
prioritisation of resources to other areas as STI care is
generally a low priority for GPs.
In Sweden, chlamydia care at GP level is provided
within the capitation for registered patients, i.e. covered
by the County Council. Further, some counties provide
chlamydia diagnostic tests free of charge to the GP (e.g.
Örebro County but not Uppsala County). The patients
can go in every county to any GP for testing and treat-
ment without incurring any cost.
In France patients pay GPs and laboratories directly for
services rendered and afterwards are partially reimbursed
by the National health insurance system. However, only
65% of the cost for opportunistic testing is reimbursed to
patients belonging to risk groups only (although these risk
groups are not specified). Testing is free for patents in
STI, family planning and antenatal clinics.
In Estonia, 50% of the STI treatment medication costs
are reimbursed to patients, and in England, patients do
not have to pay for the medication if they are treated by
a Genitourinary Medicine clinic, they are in full time
education and under 18 years of age, in receipt of cer-
tain benefits, or are prescribed treatment under a
Patient Group Direction.
Discussion
Our aim was to compare chlamydia care in countries where
testing is provided by most GP practices (England, Sweden)
with that in countries where GP testing is not provided or
is provided only to a very limited extent (France, Estonia)
to delineate factors that may be related to the future scope
and volume of chlamydia care provided by GPs.
Table 2 Chlamydia management and control activities in study countries
England Estonia France Sweden
Written guidelines or recommendations
about chlamydia diagnosis and
case management
UK National Guideline for the







recommendations on la atory
diagnostic procedure ly
The Board of County
Medical Officers 2010
British Association for Sexual






Yes Yes Yes Yes
Since 2003: recommenda ns for
screening at- risk wo n
aged 15–25 [32]
Repeat test recommended for
patients with a positive
chlamydia test
Repeat test of positives 3
months after diagnosis
Repeat test of positives
3 months after diagnosis
No Test for cure
Additional testing for other STIs
or HIV recommended for those
with positive chlamydia test
Yes Yes Yes Yes
Including HIV Including HIV
Partner notification recommended Yes (patient and provider referral) Yes (patient referral) Yes (patient referr Yes (patient and provider referral)
Written guidelines or recommendations
about chlamydia diagnosis and case
management specifically for GPs
Yes, contained within National Chlamydia
Screening Programme Core Guidance
6th Edition 2012 and BASHH 2006
No No Yes, Recommendations from the
Board of County Medical officers, 2010
Royal College of General Practitioners
2013 Sexually Transmitted Infections
in primary care guidelines
National chlamydia screening program Yes No No No
National surveillance data for chlamydia
routinely reported
Yes Yes No (Not routinely, but inte ttently) Yes
Chlamydia cases reported by Laboratories Settings in which they
are diagnosed
(= physicians)
Surveillance network of v nteer
(not compulsory, not reim rsed)
laboratories that report d ction
rates of chlamydia (ReN hla)
Settings in which they are
diagnosed (= physicians)
Settings providing chlamydia testing
(GUM = genitourinary medicine clinic;
STI = sexually transmitted infections
clinics; GYN = gynecology clinics)
GUM, sexual and reproductive health
services, GPs, pharmacies, termination
of pregnancy providers, internet based
Youth Health Centres;
GYN; STI; internet based
self-sampling;
GP; STI, GYN; Family pl ing
clinic; Internal medicine cialist
GP; STI, GYN; ER; internet based
self-sampling; Family planning
































Table 2 Chlamydia management and control activities in study countries (Continued)
services, other (including targeted
youth services)
Main site for chlamydia testing Men/women - GUM, primary
care settings including GP
Women - GYN; Youth - free and Women: Family planning
Men – STI clinic anonymous family or GP Men: STI clinic or GP
Youth – Youth
health centres
planning clinics Youth - Youth surgeries
Breakdown of chlamydia cases by
setting for diagnosis or
treatment (top 3)
STI/GUM 29% STI 20% Presumed to originate STI 25%
GP 18% GP 6% mainly from Youth Health GP 10%
Family planning 15% Youth Health
Centres 30%
Centres and STI, Family Youth Health Centres 40%




















Table 3 Primary health care provision indicators in study countries
England Estonia France Sweden
Number of general practitioners
premises/surgeries
8230 in England 802 59 838 GPs registered in
private practices
5000
70 per 100 000 62 per 100 000 92 per 100 000 53 per 100 000
Main type of GP services Small group practices: typically 2–3 GPs and
nurses (45%); larger ones 5–9 GPs and
3–4 nurses (38%)
Single handed practices (70%); small
group practices (20%); 1–2 nurses
Small group practices (54%),
others single handed.
Medium size practices: 4–5 GPs, 10
nurses, 2 lab technicians, one social
worker
No nurses
Is training for sexually transmitted disease
care (during residency) mandatory for GPs?
Not mandatory, but GPs studying it
must meet key competencies
Yes (but extremely limited) No No, but often done
Proportion of people aged 16–24
visiting GP per year
75% female, 63% male% [26] 71% [27] 75% [28] 60%*




















Table 4 Chlamydia care in GP practices in study countries
England Estonia France Sweden
GPs regularly provide STI
care including chlamydia
Yes No Yes, usually only for
symptomatic cases
Yes
% of GP services performing
any testing for genital
CT infection
88% < 5% < 10% >80%




Yes No No Yes
Do GP services test
symptomatic cases for
chlamydia?




testing in GP settings
NAAT* NAAT NAAT NAAT
Specimens usually used
by GPs for diagnosis of
symptomatic cases
Men urine; Women –
physician collected
cervical swab




Men urine; Women – physician
collected cervical swab




by GPs for screening tests
Men urine; Women –
(self-collected) vaginal
swabs or urine
Men – urine or physician
collected urethral swab;
women – physician collected
swab (endocervical) or urine
Men - urine samples: women -
physician collected
swab (endocervical)
Men urine; Women –
(self- collected)
vaginal swabs
*Nucleic acid amplification tes.
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disease (genital chlamydia infection) or the organization of
GP care provision. In all four countries, a substantial pro-
portion (~70%) of population at most risk of chlamydia
(young people aged 16–25 years) annually visit GPs. Im-
portantly, in all the countries examined, testing for chla-
mydia is available in the public sector, and using NAAT
methodology (NAAT is convenient, logistically straightfor-
ward, facilitates sampling, and highly specific/sensitive). An
important similarity was that chlamydia care costs are re-
imbursed to the relevant parties (GPs in England, Sweden
and Estonia; and patients in France) by the National health
insurance system or its equivalent in participating countries
(although not necessarily all the costs).
The countries where GPs provide chlamydia care regu-
larly (England, Sweden) have written chlamydia manage-
ment guidelines developed specifically for GPs, and STI
management was more firmly established in the GP train-
ing curriculum either formally (England) or informally
(Sweden). In comparison, in France, training for sexuallyTable 5 Payment for chlamydia and STI care in GP settings
England
Are any of the costs of [health care services
for the diagnosis and treatment of individuals
with chlamydia] covered or reimbursed to the
GP service by the national health insurance
system or its equivalent?
Yes
National Health Service
Are the costs of […] covered or
reimbursed to patients?
Yes
(dtransmitted disease care during GP training was not
mandatory and in Estonia training was extremely limited
(although formally in place).
A prerequisite for effective chlamydia control is the exist-
ence of a comprehensive and effective control programme,
with a broad consensus on a strategy for chlamydia control,
taking into account specific national opportunities and limi-
tations, and addressing available and future services and re-
sources. National strategies or plans on STI control that
specifically mention chlamydia are in force in England and
Sweden. England is the only country in the European
Union implementing a national chlamydia screening pro-
gram that offers opportunistic screening for chlamydia to
women and men under 25 years of age attending clinical
and non-clinical screening venues using non-invasive urine
or vulvo-vaginal swab samples tested via NAAT [31]. In
addition and in relation to that, England has specific chla-
mydia diagnostic targets for local authorities to reach and
therefore this incentivises them to take forward chlamydia
Screening Programmes with GPs.Estonia France Sweden
Yes Yes, indirectly Yes
Estonian health
insurance fund
Patients pay for directly to GPs for
chlamydia care, and are afterwards
(partially) reimbursed by
the National health insurance
County Council
Yes, partially
rugs up to 50%)
Yes, partially (all services up to 65%) Yes
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http://www.biomedcentral.com/1471-2458/14/1147The historical provision of STI care influences current
GP staff attitudes and confidence to provide chlamydia
testing in the primary care setting. In all countries the ma-
jority of STI diagnostic tests have been undertaken in the
specialised genito-urinary medicine or youth/family plan-
ning of gynaecology settings. And indeed this continues to
be the major provider of chlamydia testing, but we contend
that the GP practice could play a much greater role. Chla-
mydia screening as a national program has only been
undertaken in England since 2003 and is not yet embedded
as routine [32]. In Estonia and France it may be difficult to
change long-term traditions, especially when the special
training is limited. An intervention study conducted in the
South West of England was successful in increasing chla-
mydia testing rates in general practice through providing
training, resources and support to GP staff [33]. The results
of this study were intended to inform the adaptation of that
intervention to implement a chlamydia testing training
package for with general practice staff in England, Estonia,
France and Sweden to ensure cultural and logistical issues
were addressed in its development.
A recent review on potential advantages of chlamydia
screening concluded that young people are generally
positive about chlamydia screening, and general practice
could be one of their preferred venues [34].
Several studies assessing care provision in GP surgeries
have documented substantial barriers for the delivery of
preventive services – such as lack of time during the
visit, inadequate insurance reimbursement, belief that
patient will not wish to discuss or comply with recom-
mendations, and lack of physician expertise in counsel-
ling techniques [35]. Consistent with the finding that
time is a salient barrier, Zyzanski and colleagues have
shown that high-volume physicians perform fewer pre-
ventive services [36]. A study from the USA, has shown
that to fully satisfy the US Preventive Services Task Force
recommendations, 1,773 hours of a physician’s annual
time, or 7.4 hours per working day, is needed for the
provision of preventive services [35]. This confirms that
time may well be a major barrier to public health initia-
tives in primary care and emphasises the need for priori-
tising interventions to be delivered and any intervention
to be quick and easy.
Our study has limitations. A significant limitation is
that we did not examine individual features of primary
prevention present in the study countries. Further, we
only assessed a small number of countries, and we are
not able to generalise our results widely. However, we
believe that this analysis has provided useful insights in
an area where research is limited.
Conclusions
In countries where chlamydia testing is provided by GPs
(England, Sweden) a national strategy or plan on STIcontrol that specifically mentions chlamydia was in
force, chlamydia care guidelines for GPs were in place and
STI management was more firmly established in the GP
residency training curriculum, either formally (England)
or informally (Sweden), than in the other countries.
Future research on the effectiveness of chlamydia
screening (also in the context of general practice care)
and program provision should reflect national needs and
the prevention of complications. Our findings indicate
that to attain any increase in the provision of testing for
and diagnosis of STIs in the general practice setting
countries with low chlamydia and STI testing will prob-
ably need nationally agreed guidance, nationally agreed
STI training within the GP residency curriculum, and
much on-going education support and finances within
the general practice setting. We are now developing an
educational resource that can be implemented across
countries with different chlamydia and STI testing
provision in the GP setting (www.STItraining.eu).
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